Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma

Kinan Alhallak, Amanda Jeske, Pilar De La Puente, Jennifer Sun, Mark A. Fiala, Feda Azab, Barbara Muz, Ilyas Sahin, Ravi Vij, John F. DiPersio, Abdel Kareem Azab

Blood (2021) 138 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2021-153832

Published: 2021

Journal Articles

Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma

Barbara Muz, PhDMSc, Katherine Wasden, Kinan Alhallak, BSc, Amanda Jeske, BS, Feda Azab, Jennifer Sun, BSc, Justin King, BS, Daniel R. Kohnen, MBA, Ravi Vij, MBBS, Abdel Kareem Azab, PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-142154

Published: 2020

Journal Articles

3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Retrospectively Predicts Treatment Clinical Outcomes of Multiple Myeloma Patients

Amanda Jeske, BS, Feda Azab, BPharm, Pilar De La Puente, PhD, Barbara Muz, PhDMSc, Justin King, Daniel R. Kohnen, MBA, Ravi Vij, MBBS, Abdel Kareem Azab, PhD

Blood (2018) 132 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2018-99-118888

Published: 2018

Journal Articles

Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma

Pilar De La Puente, PhD, Barbara Muz, PhDMSc, Feda Azab, BPharm, Micah John Luderer, BS, MS, Jack L. Arbiser, MD, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 2978.

https://doi.org/10.1182/blood.V126.23.2978.2978

Published: 2015

Journal Articles

Novel Method to Detect Minimal Residual Disease in Multiple Myeloma Predicts Recurrence Better Than CD138-Based Models

Barbara Muz, PhDMSc, Feda Azab, BPharm, Pilar De La Puente, PhD, Justin King, Micah John Luderer, BS, MS, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 2985.

https://doi.org/10.1182/blood.V126.23.2985.2985

Published: 2015

Journal Articles

Selinexor Is an Effective Cancer Treatment in Hypoxic Conditions and Synergizes with Proteasome Inhibitors to Treat Drug Resistant Multiple Myeloma

Barbara Muz, PhDMSc, Feda Azab, BPharm, Pilar De La Puente, PhD, Yosef Landesman, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 3017.

https://doi.org/10.1182/blood.V126.23.3017.3017

Published: 2015

Journal Articles

Hypoxia Induces Pgp-Mediated Carfilzomib Resistance in Multiple Myeloma Cells and HIF Inhibition Significantly Enhances Sensitivity and Response to Carfilzomib In Vivo

Barbara Muz, PhDMSc, Joseph Abraham, Feda Azab, BPharm, Pilar De La Puente, PhD, Nicholas Potter, Benjamin Minch, Farideh Ordikhani, Noha Salama, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 1286.

https://doi.org/10.1182/blood.V126.23.1286.1286

Published: 2015

Journal Articles

3D Tissue-Engineered Bone Marrow Cultures Induce Drug Resistance, De-Differentiation and Cytokine Expression Changes in Multiple Myeloma

Pilar De La Puente, PhD, Barbara Muz, PhDMSc, Feda Azab, B.Pharm, Justin King, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 2069.

https://doi.org/10.1182/blood.V124.21.2069.2069

Published: 2014

Journal Articles

A Novel and Personalized Method Using Simulation for Predicting Effective Therapeutics for Waldenströms Macroglobulinemia

Abdel Kareem Azab, BPharm, PhD, Aneel Paulus, MDMS, Feda Azab, B.Pharm, Sharoon Akhtar, MPhil, Shireen Vali, PhD, Ansu Kumar, Neeraj Kumar Singh, Shweta Kapoor, Taher Abbasi, MS, Asher Chanan-Khan, MD, Kasyapa S. Chitta, PhD

Blood (2014) 124 (21): 3024.

https://doi.org/10.1182/blood.V124.21.3024.3024

Published: 2014

Journal Articles

PYK2 Inhibitors Sensitize Hypoxia-Induced Drug Resistant Multiple Myeloma Cell

Barbara Muz, PhDMSc, Maurizio Buggio, PhD MSc, Feda Azab, B.Pharm, Anthony F. Trombino, PhD, Mahesh Padval, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4704.

https://doi.org/10.1182/blood.V124.21.4704.4704

Published: 2014

Journal Articles

Patient-Derived 3D Tissue-Engineered Bone Marrow Cultures Support Primary MM Growth

Pilar De La Puente, PhD, Feda Azab, B.Pharm, Barbara Muz, PhDMSc, Justin King, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4705.

https://doi.org/10.1182/blood.V124.21.4705.4705

Published: 2014

Journal Articles

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

Barbara Muz, PhDMSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Scott A Rollins, PhD, Richard Alvarez, MBA, Ziad Kawar, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4758.

https://doi.org/10.1182/blood.V124.21.4758.4758

Published: 2014

Journal Articles

CD138-Independent Strategy for Detecting Residual and Circulating Myeloma Plasma Cells

Barbara Muz, PhDMSc, Feda Azab, B.Pharm, de la Puente Pilar, PhD MSc, Jacob Paasch, BS, Justin King, Luderer Micah, Ravi Vij, MBBS, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 2077.

https://doi.org/10.1182/blood.V124.21.2077.2077

Published: 2014

Journal Articles

CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma

Abdel Kareem Azab, Ilyas Sahin, Feda Azab, Michele Moschetta, Yuji Mishima, Nicholas Burwick, Johann Zimmermann, Barbara Romagnoli, Kalpana Patel, Eric Chevalier, Aldo M. Roccaro, Irene M. Ghobrial

Blood (2014) 124 (12): 1905–1914.

https://doi.org/10.1182/blood-2014-02-558742

Published: 2014

Journal Articles

PI3K-Alpha Plays A Major Role In Multiple Myeloma and Its Inhibition With BYL917 Decreases Proliferation, Synergizes With Other Therapies and Overcomes Stroma-Induced Resistance

Feda Azab, B.Pharm, Shireen Vali, Nicholas Potter, Joseph Abraham, Barbara Muz, PhD, MSc, Pilar De La Puente, PhD, Taher Abbasi, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 3215.

https://doi.org/10.1182/blood.V122.21.3215.3215

Published: 2013

Journal Articles

Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma

Ilyas Sahin, MD, Feda Azab, Michele Moschetta, MD, Yuji Mishima, PhD, Brian Tsang, Patricia Maiso, PhD, Antonio Sacco, BS, Aldo M Roccaro, MD, PhD, Abdel Kareem Azab, PhD, BSPharm, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 3159.

https://doi.org/10.1182/blood.V122.21.3159.3159

Published: 2013

Journal Articles

Tumor Hypoxia Promotes Dissemination and Tumor Colonization In Waldenström Macroglobulinemia

Barbara Muz, PhD, MSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 3011.

https://doi.org/10.1182/blood.V122.21.3011.3011

Published: 2013

Journal Articles

Hypoxia Induces Drug Resistance In Multiple Myeloma

Barbara Muz, PhD, MSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Irene M. Ghobrial, MD, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 1852.

https://doi.org/10.1182/blood.V122.21.1852.1852

Published: 2013

Journal Articles

Autologous 3D Tissue-Engineered Bone Marrow For Drug Screening In MM Patients

Pilar De La Puente, PhD, Feda Azab, B.Pharm, Barbara Muz, PhD, MSc, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 132.

https://doi.org/10.1182/blood.V122.21.132.132

Published: 2013

Journal Articles

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Irene M. Ghobrial, Federico Campigotto, Timothy J. Murphy, Erica N. Boswell, Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, Farzana Masood, Diane Warren, Scott Rodig, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Jeffrey Matous

Blood (2013) 121 (8): 1296–1303.

https://doi.org/10.1182/blood-2012-06-439307

Published: 2013

NARROW

3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma

Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma

3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Retrospectively Predicts Treatment Clinical Outcomes of Multiple Myeloma Patients

Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma

Novel Method to Detect Minimal Residual Disease in Multiple Myeloma Predicts Recurrence Better Than CD138-Based Models

Selinexor Is an Effective Cancer Treatment in Hypoxic Conditions and Synergizes with Proteasome Inhibitors to Treat Drug Resistant Multiple Myeloma

Hypoxia Induces Pgp-Mediated Carfilzomib Resistance in Multiple Myeloma Cells and HIF Inhibition Significantly Enhances Sensitivity and Response to Carfilzomib In Vivo

3D Tissue-Engineered Bone Marrow Cultures Induce Drug Resistance, De-Differentiation and Cytokine Expression Changes in Multiple Myeloma

A Novel and Personalized Method Using Simulation for Predicting Effective Therapeutics for Waldenströms Macroglobulinemia

PYK2 Inhibitors Sensitize Hypoxia-Induced Drug Resistant Multiple Myeloma Cell

Patient-Derived 3D Tissue-Engineered Bone Marrow Cultures Support Primary MM Growth

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

CD138-Independent Strategy for Detecting Residual and Circulating Myeloma Plasma Cells

CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma

PI3K-Alpha Plays A Major Role In Multiple Myeloma and Its Inhibition With BYL917 Decreases Proliferation, Synergizes With Other Therapies and Overcomes Stroma-Induced Resistance

Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma

Tumor Hypoxia Promotes Dissemination and Tumor Colonization In Waldenström Macroglobulinemia

Hypoxia Induces Drug Resistance In Multiple Myeloma

Autologous 3D Tissue-Engineered Bone Marrow For Drug Screening In MM Patients

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only